Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2001

View Archived Issues

Enrollment closed in Atrix's phase III trial with four-month Leuprogel

Arena and Taisho establish receptor discovery alliance

Dey receives FDA approval for first dual-therapy nebulizer solution for use in COPD

InterMune and Boehringer Ingelheim establish codevelopment agreement for interferon gamma-1b

Intravenous formulation of Protonix approved by FDA for GERD

PAK-200 shows cardioprotective effects in guinea pig myocardium

Mechanism of gastroprokinetic effects of Z-338 discussed at recent scientific meeting

Progen and Griffith University to discover new compounds to treat inflammatory diseases

BioChem Pharma's Troxatyl enters late-stage clinical trials in AML patients

Abgenix and Diabetogen collaborate on development of anti-CD28 antibody therapy

AtheroGenics commences phase I trial with AGIX-4207 for treatment of RA

MoliChem's aerosol product for CF undergoes phase Ib clinical trials

Profile, status of Lorus's lead cancer therapeutics discussed at AACR meeting

Antitumor and antiangiogenic effects demonstrated for new VEGF-binding molecule

Peptidomimetic and small-molecule uPA inhibitors hold promise as cancer therapeutics

German launch of antimigraine Almogran imminent

Johnson & Johnson and Alza agree to merge

ROCK inhibitors investigated for potential as antiglaucoma drugs

Recently approved IOP-lowering prostaglandin highlighted at Prague glaucoma meeting

Ciclesonide to be codeveloped and copromoted by Aventis and Altana for asthma

Replagal receives positive opinion in E.U. for treatment of Fabry's disease

Camptosar approved in Canada as first-line treatment of metastatic colorectal cancer

Tryptase inhibitors and use in respiratory disorders claimed by Byk Gulden

Bayer presents newest angiogenesis inhibitor series

Substituted aromatic compounds from Takeda inhibit NO production

Novel alpha1A/1B-adrenoceptor antagonists and use in BPH and pain

Meiji Seika synthesizes dual integrin and fibrinogen antagonists

Neurotrophic agents discovered at Teijin presented in recent patent

Potential new ribonucleotide reductase inhibitors may be more effective than hydroxyurea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...